Clinical trialPhase 1Withdrawn
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
- Outcome
- Stopped earlyInsufficient accrual rate (Enrollment)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 23 December 2019
- Planned end
- 4 May 2021
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Completion Rate of oxaliplatin PEDD-PRVI; Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 1 June 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled Drug Delivery (PEDD) technology. Oxaliplatin PEDD-PRVI is administered with systemic FOLFIRI followed by FOLFIRINOX therapy for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
The treatment period consists of 6 cycles. Cycles 1 and 2 involve the regional administration of oxaliplatin via PEDD-PRVI with systemic FOLFIRI. During cycles 1 and 2, patients are evaluated on days 1, 2, 4, and 8. Cycles 3 through 6 include the systemic administration of standard of care FOLFIRINOX. During cycles 3 through 6, patients are evaluated on days 1 and 8.